亚太地区输血诊断市场预测至 2028 年 - 按产品（仪器、试剂盒和试剂）、应用（血型和疾病筛查）和最终用户（医院、诊断实验室、血库和血浆分馏公司）
No. of Pages: 140 | Report Code: BMIRE00027402 | Category: Life Sciences
No. of Pages: 140 | Report Code: BMIRE00027402 | Category: Life Sciences
新兴经济体医疗保健支出增加将推动未来几年的市场发展
医疗保健预算拨款有助于各国加强劳动力队伍并提高该部门的生产力，从而促进经济绩效。经济的快速发展使发展中国家能够提高医疗保健支出，从而能够利用技术进步建立更好的医疗服务基础设施。印度政府通过其国家卫生局机构实施了 Ayushman Bharat – 2019 年 Pradhan Mantri Jan Arogya Yojana (AB-PMJAY)。该计划促进了该国癌症患者的免费/负担得起的治疗。根据印度国家卫生局公布的数据，2019 年约有 470,133 例癌症病例接受了 AB-PMJAY 治疗。此类举措可能为输血诊断市场的公司提供利润丰厚的机会，以引进先进的输血技术亚太地区诊断市场。
市场概况
中国主导血液2022年亚太地区输血诊断市场。中国市场的增长归因于先进技术在血液相关诊断中的使用增加，以及该国献血营和血库数量的激增。国家有献血法，允许自愿无偿献血，无偿献血只能用于临床。尽管受到与大流行相关的限制，中国国家卫生健康委员会 2020 年仍记录了 1553 万人次献血。这个数字是1998年的40倍。据新华社消息，2021年1月至4月，全国登记献血512万人次。因此，临床献血数量的不断增加导致对用于筛查血型的输血诊断的高需求。
亚太地区输血诊断市场细分
亚太地区输血诊断市场根据产品、应用、最终用户和国家/地区进行细分。
雅培； BAG 诊断有限公司； Bio-Rad 实验室公司； DiaSorin SpA； F.霍夫曼-拉罗氏有限公司；南澳州格里福斯； Immucor 有限公司； Ortho 临床诊断（QuidelOrtho 公司）；商数有限；和 Thermo Fisher Scientific Inc. 是亚太地区输血诊断市场的领先公司。
Strategic insights for Asia-Pacific Blood Transfusion Diagnostics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 875.20 Million |
| Market Size by 2028 | US$ 1,380.34 Million |
| Global CAGR (2022 - 2028) | 7.9% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By 产品
|
| Regions and Countries Covered | 亚太地区
|
| Market leaders and key company profiles |
The regional scope of Asia-Pacific Blood Transfusion Diagnostics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Asia-Pacific Blood Transfusion Diagnostics Market is valued at US$ 875.20 Million in 2022, it is projected to reach US$ 1,380.34 Million by 2028.
As per our report Asia-Pacific Blood Transfusion Diagnostics Market, the market size is valued at US$ 875.20 Million in 2022, projecting it to reach US$ 1,380.34 Million by 2028. This translates to a CAGR of approximately 7.9% during the forecast period.
The Asia-Pacific Blood Transfusion Diagnostics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia-Pacific Blood Transfusion Diagnostics Market report:
The Asia-Pacific Blood Transfusion Diagnostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia-Pacific Blood Transfusion Diagnostics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia-Pacific Blood Transfusion Diagnostics Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia-Pacific Blood Transfusion Diagnostics Market
